-
Featured Authors
-
Archives
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: Industry Analysis
Recommended Reading from BIOtechNOW
We hope the dust has settled from Boston’s International Convention, and you’re ready for a busy fall schedule! Here’s just a quick post on some recent articles that have been published on BIOtechNOW that’s worth a read. 2012 Fall Event Preview – A recap of BIO’s upcoming BD events, among others. 2012 BIO Convention in China: Highlighting Cross-Border Partnering in Biotechnology – Take a deeper look at the 2nd Annual BIO China event. We’re also Read More >
Indices, IPOs, and New Drug Approvals – Update July 6th 2012
1. Stock Performance. The Nasdaq Biotech Index (NBI) continued on its path of outperforming the market, up 24.6 percent and increasing its Year-to-Date (YTD) lead over the S&P 500 which is up 8.3 percent. The Amex Biotech Index (BTK) closed out June up a hefty 34.6 percent YTD: 2. IPOs: Tesaro, Inc. (TSRO) was June’s sole U.S. IPO, raising $81M. The company was formed just two years ago and has aggressively in-licensed cancer treatments from Read More >
Business Confidence with the RFS Under Attack
This week, Biofuels Digest and BIO launched the quarterly Bioenergy Business Outlook Survey. Results from the first quarter of 2012 showed that industry optimism remained high earlier in the year, even though companies still reported difficulty in raising the capital needed for ongoing research and development and construction of demonstration and commercial biorefineries. Now that the petroleum refiners have launched a multi-million dollar pr campaign against the biofuel industry, it will be interesting to take Read More >
Biofuels & Climate Change
Leave a comment
Email This Post
Tags: 2011 Bioenergy Business Outlook Survey, 2012 BIO International Convention, Bioenergy Business Outlook Survey, biofuel, Biofuel Technology, biofuels, Biofuels Digest, biotech industry, Biotechnology Industry, Industry Analysis, renewable fuel standard
Tags: 2011 Bioenergy Business Outlook Survey, 2012 BIO International Convention, Bioenergy Business Outlook Survey, biofuel, Biofuel Technology, biofuels, Biofuels Digest, biotech industry, Biotechnology Industry, Industry Analysis, renewable fuel standard
Only a Few Public Biotechs are Profitable, but There are More of Them Today
Of the 294 biotechs trading on public exchanges today, 248 (84%) focus on drug development. Of these 248 in the biopharmaceutical space, 81, or 33% have a drug approved. Only 32 (13%) had both a product on the market and positive net income in 2011. However, this 13% represents a significant jump from the 7.5% with positive net income we calculated for 2009. Note that this comes over a time frame in which a few profitable companies were Read More >
Indices, IPOs, and New Drug Approvals – Update April 3rd 2012
1. Stock Performance. The Nasdaq Biotech Index (NBI) continued to outperform in March, maintaining its Year-to-Date (YTD) lead of 18% vs. 12% for the S&P 500. Concentrated portfolios holding Amlyin, Regeneron, and Illumina came out even higher. For example, the Amex Biotech Index (BTK) is up 29% this year mainly because it held concentrated positions in these names. Amylin (ALMN) has doubled on the FDA approval for Bydureon and post-approval buy-out rumors. Illumina (ILMN) is up 72% Read More >
